{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:44:27Z","timestamp":1648968267685},"reference-count":3,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.eururo.2016.09.036","type":"journal-article","created":{"date-parts":[[2016,10,10]],"date-time":"2016-10-10T03:05:45Z","timestamp":1476068745000},"page":"e17","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707\u2013708"],"prefix":"10.1016","volume":"72","author":[{"given":"Matthew R.","family":"Sydes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair W.S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.09.036_bib0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2016.06.041","article-title":"Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever","volume":"70","author":"Tsao","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.09.036_bib0025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clon.2016.03.006","article-title":"High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront docetaxel chemotherapy in usual clinical practice","volume":"28","author":"Tanguay","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2016.09.036_bib0030","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.clon.2016.07.004","article-title":"Response to \u2018high risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront docetaxel chemotherapy in usual clinical practice\u2019, by Tanguay et al","volume":"28","author":"James","year":"2016","journal-title":"Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816306765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816306765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T20:21:48Z","timestamp":1536351708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816306765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":3,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0302283816306765"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.09.036","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707\u2013708","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.09.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.06.041","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}